Myeloma IRF4 target genes - Agilent

Molecular subtypes of DLBCL have distinct chromosomal aberrations

Prediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab

Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma

Highly Recurrent MYD88 Mutations That Promote Human Lymphoma Cell Survival

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

Determining IRF4 target genes using RNA interference in ABC-DLBCL and MM

Co-addiction to IRF4 and SPIB in ABC-DLBCL

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

DLBCL cell-of-origin by gene expression in FFPET

Oncogenic MyD88 Mutants Require Toll-like Receptors

Blockade of oncogenic IkappaB kinase activity in ABC DLBCL by small molecule BET protein inhibitors

Cell intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses

Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Lymphoid Malignancies

FOXP1 in ABC DLBCL

ATM-deficient B cell lymphomas

Regulation of normal B cell differentiation and malignant B cell survival by OCT2 (expression)

Regulation of normal B cell differentiation and malignant B cell survival by OCT2